Swiss Life Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Swiss Life Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,885	Closed	-$1.38M	–	1687
2026 Q1	$1.38M	Buy	+21,885	New	+$353K	0.01%	598

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Swiss Life Asset Management's KALV Position: Q2 2026 in Review

Swiss Life Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 21,885 shares — an estimated $1.38M sold.

Swiss Life Asset Management first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $1.38M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Swiss Life Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Swiss Life Asset Management sold 21,885 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.38M.
Swiss Life Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Swiss Life Asset Management's KalVista Pharmaceuticals position peaked at $1.38M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.